Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.44 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4578708 | 0.81 | EPHX2 (0.50) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL15615966 | 0.80 | ALDH1A1 (0.41) | EPHX2ALDH1A1NPC1 | |
| SCHEMBL10282539 | 0.80 | ALDH1A1 (0.67) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL14996187 | 0.80 | EPHX2 (0.53) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL7487836 | 0.80 | EPHX2 (0.53) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL4518519 | 0.79 | GNAI3 (0.51) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL21429965 | 0.79 | ALDH1A1 (0.41) | EPHX2ALDH1A1NPC1 | |
| SCHEMBL4487574 | 0.78 | EPHX2 (0.51) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL16077702 | 0.78 | EPHX2 (0.51) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 | |
| SCHEMBL11717 | 0.78 | GNAI3 (0.61) | EPHX2ALDH1A1CHRNB2CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022012623-A1 | DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BEIGENE, LTD. (KY) | 2022-01-20 | — | — | WO | disclosed |
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | ORION CORPORATION (FI) | 2019-07-02 | — | — | US | disclosed |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | ORION CORPORATION (FI) | 2018-07-05 | — | — | US | disclosed |
| US-9611290-B2 | Trypsin-like serine protease inhibitors, and their preparation and use | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2017-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336697-B2 | Spiro[cyclobutane-1,3′-indolin]-2′-one derivatives as bromodomain inhibitors | BRD4, BRD3, BRD1 | EPHX2 3397/4885ALDH1A1 1772/4885CHRNB2 412/4885 |
| US-20180186739-A1 | SPIRO[CYCLOBUTANE-1,3'-INDOLIN]-2'-ONE DERIVATIVES AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD1 | EPHX2 3426/4885ALDH1A1 1786/4885CHRNB2 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.